Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atf3 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intraperitoneal, Intravitreal, Inhalation, Intranasal, Topical, Ophthalmic, Intratumoral, Intralesional
01
Overview
Atf3 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Activating Transcription Factor 3 (ATF3). ATF3 is a member of the ATF/CREB family of transcription factors that is induced by various stress signals, including chronic ethanol exposure. In pancreatic β-cells, ATF3 acts as a negative regulator of glucose homeostasis by binding to the glucokinase (Gck) promoter, leading to Gck down-regulation and subsequent β-cell dysfunction. By utilizing RNA interference to degrade ATF3 mRNA, Atf3 siRNA restores Gck expression, ameliorates impaired glucose tolerance, and reduces insulin resistance. It is investigated as a potential therapeutic target for treating type 2 diabetes and alcohol-induced metabolic impairment.
- Other names
- ATF3-silencing RNAATF-3-silencing RNAATF 3-silencing RNAsiRNA-ATF3siRNA-ATF-3siRNA-ATF 3activating transcription factor 3 small interfering RNA
02
Targets
ATF3 (Activating transcription factor 3)
Beyond the preview
Go deeper on atf3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atf3 siRNA.